Clinical Validation vs. Clinical Evidence: What Payers and Hospitals Actually Require

There is a critical distinction that most diagnostics founders discover too late: the evidence required to clear a product with FDA and the evidence required to convince a hospital to use it or a payer to reimburse it are not the same evidence. FDA clearance establishes that a device is safe and performs as labeled. It says nothing about whether the device changes clinical outcomes, reduces costs, or improves care delivery. Hospitals and payers care about those latter questions, and a cleared product without answers to them will sit in a regulatory filing cabinet while the sales team loses every deal.

Clinical validation, in the narrow regulatory sense, refers to the analytical and clinical performance studies that establish a test's accuracy relative to a reference standard. For a diagnostic test, this means measuring sensitivity — the probability that the test is positive when the condition is present — and specificity — the probability that the test is negative when the condition is absent — in a well-characterized patient population. These studies demonstrate that the test works. They do not demonstrate that using the test changes what clinicians do or improves what happens to patients.

Clinical utility is the concept that bridges test performance and clinical value. A test has clinical utility when its result changes clinical management and that change leads to better patient outcomes. Demonstrating clinical utility requires a different study design than analytical validation — typically a prospective interventional trial where one group of patients is managed using the test and another group is managed without it, and outcomes are compared. Clinical utility studies are expensive, take years, and are frequently not required for regulatory clearance, which is why so many cleared diagnostics lack them — and why so many cleared diagnostics struggle to achieve commercial adoption.

Hospital value analysis committees — often called VACs — are the internal review bodies that evaluate new products before a health system approves them for procurement. VACs typically include clinicians, pharmacists, supply chain officers, quality staff, and financial analysts. They evaluate clinical evidence, total cost of ownership, workflow impact, and health system strategic priorities. A product presented to a VAC with only regulatory clearance and analytical validation data will almost always be asked for more — specifically, outcome data showing that using the product leads to better or cheaper care compared to current practice.

Health technology assessment, or HTA, is the formal process used in many healthcare systems — and increasingly by large payers in the United States — to evaluate whether a new technology provides sufficient clinical and economic benefit to justify coverage or inclusion on a formulary. HTA bodies like the National Institute for Health and Care Excellence in the UK, or NICE, and commercial payer medical policy teams in the US evaluate systematic reviews of the evidence, cost-effectiveness models, and comparative effectiveness data. A diagnostics company targeting covered reimbursement in any major market must understand which HTA frameworks apply and design its evidence program to satisfy them.

Comparative effectiveness research compares a new diagnostic or device against the current standard of care rather than against a placebo or no-testing baseline. This is the type of evidence that HTA bodies and sophisticated hospital systems find most persuasive. The question is not whether your test is accurate in an idealized study population — it is whether your test is more accurate, faster, safer, or cheaper than what clinicians currently use and whether those differences translate into better outcomes at a cost that health systems can justify. Companies that design studies only to demonstrate absolute performance, rather than performance relative to alternatives, build evidence packages that win regulatory arguments but lose commercial ones.

Real-world evidence — data collected from electronic health records, claims databases, registries, and post-market surveillance programs rather than controlled trials — is playing an increasingly important role in coverage and adoption decisions. Real-world evidence can supplement clinical trial data to demonstrate that a test performs as expected in routine care, that its clinical utility persists across diverse patient populations, and that downstream cost offsets are measurable in actual health system data. For diagnostics, building a data strategy that generates real-world evidence from early commercial deployments is no longer optional — it is the mechanism by which the second and third commercial contracts are won.